1. Home
  2. FLNA vs COCH Comparison

FLNA vs COCH Comparison

Compare FLNA & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FLNA

Filana Therapeutics Inc. Common Stock

N/A

Current Price

$1.25

Market Cap

61.8M

Sector

Health Care

ML Signal

N/A

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

HOLD

Current Price

$0.63

Market Cap

49.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNA
COCH
Founded
1998
1995
Country
United States
United States
Employees
20
47
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
61.8M
49.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FLNA
COCH
Price
$1.25
$0.63
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
346.0K
123.1K
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$1.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.16
$0.36
52 Week High
$2.03
$1.89

Technical Indicators

Market Signals
Indicator
FLNA
COCH
Relative Strength Index (RSI) 40.61 41.74
Support Level $1.16 $0.64
Resistance Level $1.80 $0.73
Average True Range (ATR) 0.10 0.04
MACD -0.00 -0.01
Stochastic Oscillator 4.41 25.58

Price Performance

Historical Comparison
FLNA
COCH

About FLNA Filana Therapeutics Inc. Common Stock

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

Share on Social Networks: